Articles

About Authors:
Mr. Satyanand Tyagi
President, Tyagi Pharmacy Association & Scientific Writer,
Chattarpur, New Delhi, India.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 50 Publications (42 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 50 publications, 11 are International Publications).
sntyagi9@yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S. The maize is rich in anthocyanins (also known as flavonoids), which are reported to have anti-diabetic properties. Scientists from the Department of Food and Nutrition and Department of Biochemistry at Hallym University in Korea investigated the cellular and molecular activity of purple corn anthocyanins (PCA) to determine whether and how it affects the development of diabetic nephropathy (DN). Their findings suggest that PCA inhibits multiple pathways involved in the development of DN, which may help in developing therapies aimed at type 2 diabetes and kidney disease. The aim of present article is to provide in depth knowledge about Purple Corn, their clinical and biological utility as well as their role in treatments of type 2 diabetes and kidney disease. An attempt is also made to focus on compounds found in purple corn which may aid in developing future treatments for type 2 Diabetes as well as kidney disease.

{ DOWNLOAD AS PDF }

About Authors:
*Nilesh Sovasia, Prof.Sanjeev Thacker, Arshad Hala
Seth G.L.Bihani S.D.College Of Technical Education,
Institute Of Pharmaceutical Science & Drug Research,
Sri Ganganagar,Rajasthan,India
*nilesh.sovasia@yahoo.com

ABSTRACT
Diuretic agents are very useful for several critical conditions like hypertension, heart failure, renal failure, nephrotic syndrome, and cirrhosis.The various methods for screening of Diuretic agents provides useful tool to evaluate the safety and effectiveness of the drugs.It is also useful for determining the dose lavel of particular class of diuretic agents.

About Authors:
Rambabu.CH*, V. V. V. S. P. Apparao, Miss. M.  Muthulakshmi, V. Ananth.
aPG-Student, Department Of Pharmaceutical Analysis,
KMCH College of Pharmacy,
Kalapatti Road, Coimbatore– 641 048, INDIA.
*ramgepharma@gmail.com

ABSTRACT:
At present, simultaneous determination of drugs in the combination dosage forms has been enjoying renaissance in the field of pharmaceutical analysis. Paracetamol, a classical antipyretic in combination with a novel antispasmodic drug, drotaverine hydrochloride provides a synergistic effect in the treatment of spasms. From the reviewed literature, it was simultaneous uv-spectrophotometric methods have not yet been developed for the determination and quantification of paracetamol and drotaverine hydrochloride. The λmax of paracetamol is 257 nm and that of drotaverine hydrochloride were scanned and found to be 308 nm, 352 nm. Both paracetamol and drotaverine hydrochloride were found to have significant absorbance of the λmax   of each other and total absorbance was equal to the sum of the absorbance of paracetamol and drotaverine hydrochloride individually measured. So the present study involves the uv-spectrophotometric method development for the simultaneous determination of paracetamol and drotaverine hydrochloride by using simultaneous equations method. The mean % recoveries from this method were found to be 100.76% and 100.17% for paracetamol and drotaverine hydrochloride respectively proving that the method is accurate.

About Authors:
Segu Sairam*, Mulla Mahaboob Basha, S Ananda Thangadurai, V Kranthi kumar
Swamy vivekanandha college of pharmacy, dept. Of pharmaceutical analysis,
Elayampalayam, tiruchengode – 637205.
*Sairampharma2020@gmail.com

ABSTRACT
A simple, sensitive and specific method reverse phase - high performance liquid chromatography (RP-HPLC) have been developed and validated for the estimation of Temozolomide in its Pharmaceutical dosage form.
Estimation of Temozolomide by using RP-HPLC coupled with UV
An isocraticREVERSE PHASE - HIGH PERFORMANCE LIQUID CHROMATOGRAPHY method was developed and validated for the estimation of Temozolomide in its Pharmaceutical dosage forms. The separation of the analytes was performed on aDevelosil ODS MG.5 (150×4.6mm),5µm, with mobile phase containing (0.5% w/v glacial acetic acid) named as Solution-A  :  Methanol  [90 : 10, v / v] was used. The flow rate was 1 ml min^-1 and separation was monitored by UV detection at 254 nm. Chromatogram showed peak at a retention time of 7.306 ± 0.009 min. validation of the method for linearity and range, intra-day and inter-day precision, accuracy, specificity, recovery, ruggedness, robustness and limits of detection and quantification were obtained as 0.598 µg / ml and 1.81 µg / ml respectively. The calibration plot was linear from 20-60 µg ml^-1 and the correlation coefficient was 0.999.The proposed method is fast, accurate and precise for the quantitative determination of Temozolomide capsules.

[adsense:336x280:8701650588]

About Authors:
Satyanand Tyagi*
*President, Tyagi Pharmacy Association & Scientific Writer,
Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 49 Publications (41 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 49 publications, 11 are International Publications).
*sntyagi9@yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Erlotinib is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR). It is marketed in the United States by Genentech and OSI Pharmaceuticals and elsewhere by Roche. In lung cancer, it extends life by an average of 3.3 months at a cost of CDN $ 95,000. The hydrochloride salt of a quinazoline derivative of the drug shows antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:
* Non-small cell lung cancer that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients who have already been treated with other chemotherapy.
* Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.

Erlotinib hydrochloride is also being studied in the treatment of other types of cancer. The aim of present article is to provide in depth knowledge about the drug Erlotinib as well as its role in treatment of non-small cell lung cancer as well as pancreatic cancer.The review has also focused about chemistry, pharmacology as well as clinical trial studies of the Erlotinib.

About Authors:
Amar Patil*, Shraddha Kanase
M.Pharm (Pharmacology)    
Department Of Pharmacology, Tatyasaheb Kore College Of Pharmacy,
Warananagar. Dist;Kolhapur, India .
*appatil.tkcp@gmail.com

Abstract:
Solanum Xanthocarpumhas been known traditionally in Indian system of medicine for the treatment of various metabolic disease and disorders. Since, the present study was carried out to know its applicability in urolithiasis condition. In the present study, extracts of Solanum Xanthocarpumwas prepared with Ethanol and used for evaluation of antiurolithiatic activity. In this study we systematically evaluated its property by using Ethylene Glycol induced Albinorats. This study also involves state of the art animal model to elucidate its probable mechanism of industrial guidelines of FDA, USA for pre-clinical evaluation of anti-Nephrolithiasis drugs.